Advancing Care in HR+/HER2- BC: From Node-Positive High-Rish EBC to MBC

Introduction

Take This Event

Breast cancer management continues to evolve rapidly, particularly in patients with HR+/HER2− disease across early and metastatic settings. This scientific broadcast aims to highlight recent advances in the treatment continuum, with a specific focus on node-positive high-risk early breast cancer (EBC) and the transition to metastatic breast cancer (MBC).

Objectives

To enhance healthcare professionals’ understanding and practical application of current evidence in the management of HR+/HER2− breast cancer across early and metastatic settings, with a focus on optimizing treatment decisions for node positive high risk early breast cancer and disease progression to metastatic breast cancer.

Speaker

Prof. Matteo Lambertini

Associate Professor and Consultant in Medical Oncology at the University of Genova, Italy.

Prof. Nadia Harbeck

Director of the Breast Center and Chair for Conservative Oncology, Department of OBGYN, LMU Hospital, Munich, Germany.

Prof. Huiping Li

Head of Department of Breast Oncology at Peking University Cancer Hospital, China.
Chair of the Breast Cancer Committee, Chinese Medical Women's Association, China